pI: 8.519 |
Length (AA): 818 |
MW (Da): 88783 |
Paralog Number:
0
Signal peptide: N | GPI Anchor: N | Predicted trans-membrane segments: 14
Targets have been classified into druggability groups (DG) according to their druggability score in network driven prioritizations. DGs range from 1 to 5; the higher the group number, the higher the chance of the target to be druggable
Modbase 3D models:
There are 5 models calculated for this protein. More info on
these models, including the
models themselves is available at:
Modbase
Target Beg | Target End | Template | Template Beg | Template End | Identity | Evalue | Model Score | MPQS | zDope |
---|---|---|---|---|---|---|---|---|---|
205 | 272 | 4fxk (B) | 708 | 795 | 17.00 | 0 | 0.05 | 0.15933 | -0.03 |
285 | 478 | 1c8s (A) | 7 | 222 | 12.00 | 0.57 | 0 | 0.232664 | 0.52 |
346 | 568 | 4fc4 (A) | 16 | 247 | 12.00 | 0.79 | 0 | 0.328116 | -0.08 |
649 | 698 | 4xk8 (H) | 75 | 131 | 36.00 | 0.63 | 0.06 | 0.166625 | 1.13 |
680 | 813 | 4yzf (A) | 678 | 800 | 37.00 | 0.66 | 0.04 | 0.136314 | 2.04 |
Help me make sense of these data.
A more detailed description of these scores is available at the Modbase Model Evaluation Help Pages, and in the papers referenced therein.
PDB Structures:
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Upper 60-80% percentile | VEG Tachyzoite, ME49 Tachyzoite, ME49 merozoite, ME49 Bradyzoite. | Gregory Hehl AB Sibley/Greg |
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Mid 40-60% percentile | ME49 Oocyst. | Fritz HM |
Sibley/Greg | ToxoDB |
Fritz HM | Transcriptomic analysis of toxoplasma development reveals many novel functions and structures specific to sporozoites and oocysts. |
Gregory | ToxoDB |
Hehl AB | Asexual expansion of Toxoplasma gondii merozoites is distinct from tachyzoites and entails expression of non-overlapping gene families to attach, invade, and replicate within feline enterocytes. |
Ortholog group members (OG5_129435)
Species | Accession | Gene Product |
---|---|---|
Arabidopsis thaliana | AT3G45040 | putative dolichol kinase |
Babesia bovis | BBOV_II007580 | hypothetical protein |
Brugia malayi | Bm1_07130 | hypothetical protein |
Candida albicans | CaO19.7893 | C terminus of integral membrane dolichol kinase |
Candida albicans | CaO19.7894 | N terminus of integral membrane dolichol kinase |
Candida albicans | CaO19.261 | integral membrane dolichol kinase |
Caenorhabditis elegans | CELE_Y56A3A.36 | Protein Y56A3A.36 |
Cryptosporidium hominis | Chro.20170 | transmembrane protein 15; cDNA sequence BC026973 |
Cryptosporidium parvum | cgd2_1560 | hypothetical protein |
Dictyostelium discoideum | DDB_G0285689 | hypothetical protein |
Drosophila melanogaster | Dmel_CG8311 | CG8311 gene product from transcript CG8311-RA |
Echinococcus granulosus | EgrG_000683900 | dolichol kinase |
Echinococcus multilocularis | EmuJ_000683900 | dolichol kinase |
Homo sapiens | ENSG00000175283 | dolichol kinase |
Leishmania braziliensis | LbrM.34.2840 | dolichol kinase, putative |
Leishmania donovani | LdBPK_352980.1 | dolichol kinase, putative |
Leishmania infantum | LinJ.35.2980 | dolichol kinase, putative |
Leishmania major | LmjF.35.2930 | dolichol kinase, putative |
Leishmania mexicana | LmxM.34.2930 | hypothetical protein, conserved |
Loa Loa (eye worm) | LOAG_12687 | hypothetical protein |
Mus musculus | ENSMUSG00000075419 | dolichol kinase |
Neospora caninum | NCLIV_035680 | Phosphatidate cytidylyltransferase family protein, related |
Oryza sativa | 9269270 | Os02g0147200 |
Oryza sativa | 9266165 | Os02g0142250 |
Oryza sativa | 4328285 | Os02g0146500 |
Onchocerca volvulus | OVOC9320 | Dolichol kinase homolog |
Saccharomyces cerevisiae | YMR013C | Sec59p |
Schistosoma japonicum | Sjp_0060110 | ko:K00902 dolichol kinase [EC2.7.1.108], putative |
Schistosoma mansoni | Smp_048540 | hypothetical protein |
Schmidtea mediterranea | mk4.001889.05 | |
Trypanosoma brucei gambiense | Tbg972.9.7840 | hypothetical protein, conserved |
Trypanosoma brucei | Tb927.9.12790 | dolichol kinase, putative |
Trypanosoma cruzi | TcCLB.510659.120 | dolichol kinase, putative |
Trypanosoma cruzi | TcCLB.507013.10 | dolichol kinase, putative |
Toxoplasma gondii | TGME49_271170 | dolichol kinase |
Trichomonas vaginalis | TVAG_182910 | dolichol kinase, putative |
Gene/Ortholog | Organism | Phenotype | Source Study |
---|---|---|---|
Tb09.211.3740 | Trypanosoma brucei | no significant loss or gain of fitness in bloodstream forms (3 days) | alsford |
Tb09.211.3740 | Trypanosoma brucei | no significant loss or gain of fitness in bloodstream forms (6 days) | alsford |
Tb09.211.3740 | Trypanosoma brucei | significant loss of fitness in procyclic forms | alsford |
Tb09.211.3740 | Trypanosoma brucei | no significant loss or gain of fitness in differentiation of procyclic to bloodstream forms | alsford |
YMR013C | Saccharomyces cerevisiae | inviable | yeastgenome |
TGME49_271170 this record | Toxoplasma gondii | Probably essential | sidik |
blattner | Systematic mutagenesis of the E. coli (MG1655) genome | J Bacteriol 2004, 186:4921-4930 |
shigen | Profiling of E. coli Chromosome (PEC) | National Institute of Genetics, Japan |
yeastgenome | Systematic deletion of yeast genes | Saccharomyces Genome Database |
gerdes | Experimental determination and system-level analysis of essential genes in E. coli MG1655 | Gerdes et al., J Bacteriol. 2003 185:5673-84 |
wormbase | C. elegans RNAi experiments | WormBase web site, http://www.wormbase.org, release WS170 |
alsford | High-throughput phenotyping using parallel sequencing of RNA interference targets in the African trypanosome | Genome Res 2011, 21:915-924 |
keio | Systematic single-gene knock-out mutants of E. coli K12 | The Keio Collection |
neb | C. elegans RNAi phenotypes | Data obtained from Wormbase WS150, curated by K. Chaudary and T. Carlow, New England Biolabs |
nmpdr | Genome-scale essentiality datasets from published studies (M. tuberculosis) | National Microbial Pathogen Data Resource |
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please contact us.